HealthXL Network

2015

2

Abir Sen

Mr. Abir Sen is the Co-Founder of Gravie, Inc. and serves as its Chief Executive Officer. Mr. Sen co-founded Bloom Health Corporation in 2009 and served as its Chief

Executive Officer until November 19, 2012. Mr. Sen also co-founded RedBrick Health Corporation and served as its Chief Strategy Officer. He was responsible for

RedBrick's product development, corporate development and strategic planning. Mr. Sen served as an Executive Officer for Definity Health, a health plan service of

Unitedhealth Group Inc. He co-founded Definity Health and most recently headed up Strategy & Development for Definity. In that role he was responsible for the Strategy,

Business Development and Research Groups and led all strategic planning, working with the rest of Definity leadership as well as with the other business segments within

UnitedHealth Group. Mr. Sen also led the business planning and launch of the Healthcare Transformation group, a segment aimed at providing differentiated service and

innovation to a premium set of customers. In addition to Definity, Mr. Sen served as an Advisor to the senior management of Fidelity Investment's Health and Welfare

Business. He also served as Vice President of Strategy for Fidelity Human Resource Services, where he wrote the business plan for and led the launch of Fidelity's HR

Consulting business. Mr. Sen started his career as a consultant with Deloitte Consulting, where he advised large managed care organizations and integrated delivery

systems on M&A and turnaround strategies. He serves as Director of Gravie, Inc. Mr. Sen has a BA in Economics from Lawrence University and an MBA from the Harvard

Business School.

CEO - Gravie

3

Dr. Aenor Sawyer

As an Assistant Clinical Professor in the UCSF Dept of Orthopaedic Surgery, Dr Sawyer combines her interest in innovation with her clinical expertise in Orthopaedics,

Physical Therapy, and Exercise Physiology to provide comprehensive musculoskeletal care. She is Director of the UCSF Skeletal Health Service and Director of the

Pediatric Bone Health Consortium, helping Pediatric to Geriatric patients optimize their bone health across their lifespans.

In addition, Dr Sawyer plays a leadership role in digital health innovation as the Associate Director of Strategic Relations for the UCSF Center for Digital Health Innovation

(CDHI) and the Associate Director of the Digital Health track in the CTSI Catalyst accelerator. She is a Clinical Adviser to ROCK HEALTH, a nonprofit Healthcare IT

incubator. In 2011 Dr. Sawyer co-founded (with Pierre Theodore) the Trinity System, a HIPAA compliant, web-based collaboration technology for virtual Tumor Board and

multidisciplinary management (MDM) of complex patients.

Dr. Sawyer has served on UCSF IT committees for Telemedicine, and Web-based/ mobile technology, and is a member of the NIH CTSA TSIG Telehealth Committee. As

an ‘Expedition Medic’ for world-record ocean rowers, she has employed remote sensing/communication to provide remote medical coverage and co-developed WEARHUB

with Archinoetics. She is now faculty advisor to the UCSF Pediatric Device Consortium, Project Director for Roboimplant. She is co-developing a safe early-mobility device

for in-patients (Mobi-us).

Associate Director, Strategic Relations – UCSF Centre for Digital Health Innovation

4

Alan O’Connel, Phd

Alan O’Connell is a Partner at Seroba Kernel. He has a background in product and business development in the pharmaceutical and biotechnology industries. Prior to

joining the firm in 2003, Alan worked in a variety of product and business development roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York),

and he also spent time in the Pharmacovigilance section at the Medicines and Healthcare Products Regulatory Agency (London). His previous venture capital experience

was gained at Estée Lauder Investments (New York) and he still sits on the scientific advisory board of the Lauder funded Alzheimer’s Drug Discovery Foundation. Alan

graduated with a Ph.D. (neurophamacology) from the National University of Ireland, Galway in 1994 and has a Master’s degree in pharmacology from the University of

London (1990). He carried out post-doctoral neuroscience research at University College, Dublin and has published in several scientific journals. Dr O’Connell sits on the

boards of: Alimentary Health; Ario Pharma; Biosensia; Crescent Diagnostics; Heart Metabolics; Opsona Therapeutics; Veryan Medical; and Xention.

Partner – Seroba Kernel Life Sciences

5

Alex Schmitz-Kohlitz

For over 20 years in the IT business, Alexander has spent the last 11 years in the Brazilian IT market during which the entrepreneur succeeded in founding, growing,

buying and selling several IT companies. He enjoys most helping young innovative IT companies become successful by taking fully advantage of the market potential in

Brazil and abroad. He holds a M.Sc. from RWTH Aachen, a DEA from Ecole Centrale Paris and a MBA from Collège des Ingénieurs in Paris. In his leisure time, he enjoys

Golf and Yoga and discovering South American Wines. Alexander, a native from German, is fluent in German, Portuguese, English, French and Italian.

Managing Partner – Polis Consulting

6

Ashifi Gogo

Ashifi founded Sproxil® in 2009 and currently serves as the company's Chief Executive Officer. Under his leadership, Sproxil developed its award-winning Mobile Product

Authentication™ (MPA™) technology. Former US President Bill Clinton described Sproxil as "a genuinely remarkable achievement... (it's) empowering... putting people in

charge of their own healthcare." Sproxil's MPA solution is now used on multiple continents and in many industries including automotive, garment and fast-moving consumer

goods. Ashifi's work has been recognized through a variety of awards and fellowships. Most recently, Sproxil was named the world's most innovative company in health

care by Fast Company, and #7 most innovative worldwide, beating 99 of the Fortune 100 companies. Ashifi was also inducted into the 40 Under 40 Class of 2012 by the

Boston Business Journal. He received a Clinton Foundation Global Initiative Outstanding Commitment Award, led Sproxil to win a grant from the United States Agency for

International Development and attract venture funding from Acumen Fund in New York.

CEO - Sproxil

7

Bill Taranto

Bill Taranto is Managing Director of Merck Global Health Innovation Fund LLC and Executive Director, Global Health Innovation Group (GHI). He is responsible for building

the GHI capability for Merck. He works across the Strategy Office, other Divisional and employee groups, and with external input to scout out new business opportunities

outside traditional pharmaceutical and vaccine projects.Bill is a member of the Innovative Ventures Board, a group that manages the identification and funding of a portfolio

of emerging businesses. Prior to joining Merck, Bill spent 18 years at Johnson & Johnson in various marketing, sales and business development roles with increasing

responsibility. In his previous position, Executive Director, Health Care Strategy & Alliances, Bill was responsible for evaluating the future healthcare environment, the

viability and impact of health care channels, and the creation of new health care business models.

Managing Director – Merck Global Innovation Fund

8

Dr. Colm Galligan

Dr Galligan is from Dublin and graduated from Trinity College Dublin medical school in 1996. He also completed an MSc (research) from Trinity in 2001. He spent 6 years

working in a variety of clinical, research and teaching posts before completing an MBA from the Smurfit Business School in2003. He subsequently worked in a variety of

Clinical Research and MedicalAffairs roles in the pharmaceutical industry with UK and European responsibility before taking up his current position with MSD in Ireland

asMedical Director in late 2007. Dr Galligan has extensive experience in setting up multinational phase 2,3 & 4 clinical trials as well as supporting the development of

InvestigatorSponsored studies. He contributes to the broader clinical research and policy development agenda in Ireland through working groups in organisations such as

IPPOSI (Irish Platform for Patient Organisations, Science & Industry). Dr Galligan is a Member of the Faculty of Pharmaceutical Medicine of theRoyal College of Physicians

of the United Kingdom, a member of the IrishPharmaceutical Healthcare Association Code Council and Chairman of the RAMI section of Pharmaceutical Medicine. He is

also currently a mentor on theHealth XL business start-up accelerator programme.

Chief Medical Officer, Ireland - Merck

9

Dan Galles

Dan is currently a director of Aventura, Spinal Kinetics and Transcend Medical and a board observer of RedBrick Health, Sanovia, Silverlink Communications and Vericare.

He was previously a director of Pathway Medical Technologies and board observer of Confluent Surgical, Guava Technologies and Valeritas. Prior to joining HLM in 2001,

Dan was an associate at Whitney & Co., a venture capital firm in Stamford, CT, where he focused on investments in the medical device, health care services and health

care information technology sectors. Prior to Whitney, he was an investment banker in the Health Care Group at Alex. Brown & Sons. Dan holds a BS from the Wharton

School of the University of Pennsylvania and an MBA from the Kellogg School of Management.

Partner – HLM Partners

10

Dr. Ena Prosser

Dr Ena Prosser is a Partner in Fountain Healthcare Partners. Ena was part of the team that raised Fountain Healthcare Partners Fund 1 in 2008. Ena is a PhD

Immunologist by training and she has a broad background in international alliance and intellectual property management. She has led rigorous due diligence projects on

technologies and products within the Specialty Pharma, diagnostic, device and biotechnology areas. Ena was formerly Director of Enterprise Ireland BIO. In this role, she

led a large team to identify, fund, protect and exploit relevant Intellectual Property, commercialise lifescience technologies and review investment opportunities in R&D.

Prior to Enterprise Ireland, Ena held various R&D and project management roles within Elan Corporation and had extensive involvement in drug delivery development,

licensing and acquisition projects over a 9-year period. Ena has a strong innovation policy background and is a member of the Irish Government Innovation Taskforce in

Intellectual Property, as well as being a council member of the Irish BioIndustry Association. She led the investments and is a board member of Genable Ltd, and Trino

Therapeutics Ltd. Ena works closely with Ireland’s leading ophthalmology research charity Fighting Blindness. Ena is an Adjunct Professor at University College Dublin and

she is a member of the Institute of Directors (Cert. Comp Dir).

Partner – Fountain Healthcare Partners

11

Esther Dyson

Esther Dyson (@edyson on twitter) is chairman of EDventure Holdings. Her primary activity is investing in and nurturing start-ups, with a recent focus on health care,

human capital and aerospace. Overall, she is fascinated by new business models, new technologies and new markets (both economically and politically). From October

2008 to March of 2009, she lived in Star City outside Moscow, Russia, training as a backup cosmonaut. Apart from this brief sabbatical, she is an active board member for

a variety of startups.

Founder - HICCup

12

Fernando Jose Martin, Phd

Fernando Martin Sanchez holds PhDs in Informatics and in Medicine, an MSc in Knowledge Engineering and a BSc in Biochemistry and Molecular Biology. He is the

University of Melbourne’s Chair of Health Informatics and the inaugural Director of the University’s Health and Biomedical Informatics Centre (HaBIC). He has worked in

the Joint Program in Biomedical Engineering between Emory University Hospital and Georgia Institute of Technology in Atlanta USA, and in the National Institute of Health

Carlos III in Madrid, Spain, where he was the CIO and then Founding Director of the Medical Bioinformatics Research Unit. His research interests cover a wide range of

topics related to the role of informatics in translational research (data linkage and integration), precision medicine (genome and exposome data processing) and

participatory health (social media, quantified-self, mobile apps).

Director, Health and Biomedical Informatics – University of Melbourne

13

Geoff Clapp

Geoffrey spent more than twelve years disrupting the telemedicine market with Health Hero Network. During his tenure at Health Hero, Geoffrey served multiple roles,

including COO and CTO. As CTO, Geoffrey designed and implemented award winning hardware and software products, including Business Week’s 2000 Product of The

Year. During his time as COO, he guided the company through the “bubble” bursting in Silicon Valley, and built the organization into the largest telehealth vendor in the

world with cornerstone customers such as the Department of Veterans Affairs and McKesson. After selling Health Hero Network to Robert Bosch, Geoffrey now serves as

advisor to Rock Health and dozens of other Health Technology Startups.

Co-founder - Better

14

Graham Love, Phd

Dr. Graham Love is CEO of the Health Research Board. Previous positions include a variety of senior roles at Science Foundation Ireland including Interim Director

General, Director of Policy and Communications and Director of Discover Science and Engineering. During his time at SFI he was responsible for the development of SFI's

2009-2013 strategy, Powering the Smart Economy, a €1.1 billion plan to drive delivery of the Government's enterprise science agenda and its successor, Agenda 2020. He

also led SFIs involvement in the Government Research Prioritisation programme and the Innovation Task Force. Graham was Chief Executive of The Multiple Sclerosis

Society of Ireland between 2005 and 2006. Before this he spent almost a decade with management consulting firm, Accenture, where he worked with clients in the

communications and high-tech sector, including Microsoft and Vodafone. He graduated with a BSc (Hons) in Pharmacology in 1993, followed by a PhD in vascular cell

biology in 1997 from University College Dublin.

CEO – Health Research Board

15

Jack Young

Jack heads up the $100M Qualcomm Life Fund (QLF) at Qualcomm Ventures, which was recently ranked as one of the most prolific venture investors in the digital health

sector. His investment interests are focused in the areas of intersection of healthcare products and services and digital/wireless technologies including: consumer-driven

wellness and fitness, chronic disease management, aging in place, transitional care, clinical trials and telehealth/telemedicine. Jack’s QLF digital health investments

include: Airstrip, AliveCor, ClearCare, Fitbit, goBalto and Telcare. In addition, he also manages QCV’s mobile technology investments at Jana, Modern Video, Argyle Data

(fka uCIRRUS), and Visage Mobile. Prior investments include: Validity (acquired by Synaptics). Prior to Qualcomm Ventures, Jack was EVP and US Country Manager at

ZTE who helped establish the company’s US market presence. He was a sales and marketing executive at Nokia following the acquisition of Amber Networks where he

was founding AVP of marketing. Early in his career, he held marketing and business development positions at 3Com, GDC, and Nortel. Jack earned a MSEE from

University of Calgary and a MBA from McGill University.

Head – Qualcomm Life Fund

16

Jan Rutherford

Jan is a Partner at SEP and focuses on medical technology, healthcare IT and pharmaceuticals.Jan joined SEP in early 2004 from Dresdner Kleinwort Capital’s life

sciences team, following earlier operational and commercial roles in the pharmaceutical industry for Quintiles, Merck Sharp & Dohme and Novartis. She played a key role

in SEP’s investment in BioVex, a cancer therapeutics company, which was sold to NASDAQ-listed Amgen in a deal worth up to $1bn and in the £20m, SEP led, investment

in matchesfashion.com. Jan also currently sits on the boards of healthcare informatics business Aridhia, and mobile patient communication and management solutions

company Exco InTouch. Jan holds an MBA from Henley Management College and is a Member of the Royal Pharmaceutical Society of Great Britain (MRPharmS).

Partner – Scottish Equity Partners

17

Dr. Joseph Wiley

Joe Wiley joined Sofinnova Ventures in 2012 to source, evaluate and support the team’s investments in Ireland. He brings over 20 years of experience in the

pharmaceutical, medical and venture industries to the firm. Joe was most recently a Medical Director at Astellas Pharma, where he focused on transplant, urology and pain.

Prior to Astellas, Joe held investment roles Spirit Capital and Inventages Venture Capital, as well as at Aberdeeen Asset Managers in the UK. Joe trained in general

medicine at Trinity College Dublin, and specialized in neurology; he is also a Member of the Royal College of Physicians in Ireland. Joe conducted Parkinson’s Disease

research at the Mayo Clinic, and has been published in many scientific journals, including Neurology and Movement Disorders. Joe completed his MBA at INSEAD.

Principle – Sofinnova Ventures

18

Dr. Joey Mason

Venture capitalist investing in young health technology companies, ranging from medical devices to apps & services. Background as entrepreneur, biotech corp dev,

investment banker and medic.

Venture Consultant – Delta Partners

19

John Brownlee

John spent 10+ years in the life sciences industry with GSK, Medtronic, Sanofi-Aventis and Merck/Schering-Plough. As VP of Sales & Marketing for Logistics Health, Inc

(acquired by United Healthcare) John launched a telemedicine platform serving large, critical-infrastructure organizations in life sciences, transportation, and energy

verticals. In 2008 John founded Quinnian Health, a telemedicine technology and services company, and ran it until the company was acquired in early 2011.

CEO – Vidscrip.com

20

Dr. John McKeon

Dr McKeon is responsible for corporate strategy and all operational activities at Allergy Standards Ltd including expanding related services and developing client

relationships. John is a medical doctor and holds a Fellowship from the Royal College of Surgeons in Ireland. Since 2000, in addition to working in Emergency Medicine, Dr

McKeon became joint founder and CEO of the Company.

Co-founder and CEO – Allergy Standards

21

Dr. John Nosta

John is a THINKER entrenched in the world of SCIENCE, MEDICINE and INNOVATION. He is regarded as one of the top global STRATEGISTS and CREATIVE minds in

the life science industry. He is also the founder of NOSTALAB--a think tank dedicated to the advancement of DIGITAL HEALTH and the EMPOWERMENT of innovation

through COMMUNICATION. A leading voice in the convergence of technology and medicine, Nosta helps define, dissect and deliberate global trends in digital health. He's

a member of the prestigious Google Health Advisory Board. He is also the #1 Kred-ranked social media influencer in health, and in the top 10 of both the Pharma100 and

HIT100 lists, and a Google Glass Explorer. John also has penned HEALTH CRITICAL for Forbes--a top global blog on health and technology. Over the past 12 months

ending August 2014, John has had over 31,000,000 #digitalhealth impressions on Twitter. John has an established reputation as a vocal advocate for strategic thinking and

creativity. He has built his career on the “science of advertising,” a process where strategy and creativity work together for superior marketing. Additionally, John has

distinguished himself as a scientific thinker. Earlier in his career, John was a research associate at Harvard Medical School and has co-authored several papers with global

thought-leaders in the field of cardiovascular physiology.

Advisory Board – Google Health

22

Joshua Krammes

Joshua Krammes is a community development director for SoftLayer Technologies, the world’s largest independent Infrastructure as a Service (IaaS) company. In his role

with SoftLayer, he is responsible for creating awareness for the SoftLayer brand, specifically the company’s efforts in fostering innovation and its investment into the global

startup ecosystem. As a community builder, Josh serves as an advisor, mentor, friend and liaison for early-stage startups to SoftLayer and the broader global startup

community. He assists SoftLayer's Community Development team at by co-managing relationships with Startup Monthly, TechStars, 500 Startups, the Global Accelerator

Network, several of the country’s premiere co-working spaces, entrepreneurial organizations and many more. He joined SoftLayer in 2012 to execute the piloted SoftLayer

Catalyst program to official launch and expansion. In the first year, the company’s program grew to incubate more than 500 startups around the globe, all seeking

mentorship, advisement, and infrastructure services as they bring product to market. Prior to SoftLayer, Krammes was fortunate to have enjoyed a successful career in

politics, NGO’s, private corporations and as an entrepreneur. As co-founder of Continuum, he has an extensive background in business development, fund raising, and

community development for companies, non-profits, municipalities and governments, and startup clients including: Sparked.com, SuperFan/BranchOut, Good.co, FitDeck,

and several others. Krammes is a life-long Big Brother volunteer, an avid runner, volunteer, traveler, hiker and surfing enthusiast. He credits all of his successes to one

simple philosophy: always asking first how you can help.

Community Development Director – Softlayer Technologies

23

Julie Papenek

If it looks challenging, it's a "maybe." If it's for a good cause, it's a "probably." If it looks really challenging and it's for a good cause, you can clear Julie Papanek's calendar.

Julie biked 4000 miles across the country to raise money for Habitat for Humanity, and has competed in triathlons to benefit the Leukemia and Lymphoma Society. It's no

secret that Julie takes the same approach when investing. Better startups just aren't enough... she wants better patient outcomes. Julie brings operational experience from

biotechnology and healthIT. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development. This

included creating commercial brand plans, forecasting, and recommending modifications to Phase III trials designs for marketed and pipeline oncology products. Recently,

she interned at Proteus Digital Health, identifying market opportunities for their digital health platform and generating business development leads. Julie also worked in

Bangalore, implementing the pilot electronic medical record system at Narayana Hrudayalaya, one of India's largest multispecialty hospital chains. Julie holds an MBA from

Stanford's Graduate School of Business, where she was the teaching assistant for the Biodesign Innovation course and an officer of the Healthcare Club. Previously, she

earned an MPhil from Cambridge University in BioScience Enterprise and a B.S. from Yale University in Molecular Biophysics and Biochemistry.

Partner – Canaan Partners

24

Dr. Kwang Lim

Associate Professor Kwang Lim joined Northern Health in 1999. Associate Professor Lim was appointed Chief Medical Officer in 2010 and is also the Clinical Services

Director Medical and Continuing Care. He is an Associate Professor in Medicine at Melbourne University as well as a Fellow of the Australian College of Physicians in

Geriatric and General Medicine. Associate Professor Lim has previous obtained a medical doctorate related to health services research and currently has research

interests in aged care and health services delivery.

Chief Medical Officer – Northern Health

25

Lisa Suennen

Lisa Suennen is Managing Partner at Venture Valkyrie Consulting, LLC, a consulting firm providing advisory services to companies, organizations and private equity firms

in the healthcare field. Additionally, Lisa is a Senior Advisor to Psilos Group, a healthcare-focused venture capital and growth equity firm that focuses on the healthcare

information technology, healthcare services and medical device sectors. Lisa was a co-founder of Psilos Group and a Partner at the firm from 1998-2014. Prior to Psilos,

Lisa was at Merit Behavioral Care (formerly American Biodyne, Inc), an $800mm behavioral healthcare company where she held various senior executive roles from its

early start-up days through exit. Previously, Lisaheld various positions in marketing and product management in companies in the high technology field. Lisa is currently a

Board Member of the Dignity Health Foundation, and Board Member of health IT company Beyond Lucid Technologies, a Board Member of medical device company

AngioScore, a member of the Qualcomm Life Advisory Board, and an Advisor to the California Health Care Foundation Innovation Fund. Lisa also serves as an Advisor to

innovation consulting firm Accelevate, Inc. She previously served as a member of the Advisory Board of the U.S. Health and Human Services Office of the National

Coordinator Investing in Innovations program. Lisa holds an M.A. in political science, a B.A. in political science and a B.A. in mass communications, all from the University

of California, Berkeley, where she is now Vice Chair of the National Advisory Council of the Institute of Governmental Studies at the University. Lisa is also a visiting

lecturer at the U.C. Berkeley Haas School of Business whereshe teaches the annual course on healthcare venture capital. Lisa also writes a widely read blog on healthcare

and healthcare investing at www.venturevalkyrie.com. She has recently published her first book, entitled: Tech Tonics, Can Passionate Entrepreneurs Heal Healthcare with

Technology, coauthored with Dr. David Shaywitz.

Managing Partner – Venture Valkyrie Consulting

26

Lynne Chou

Lynne Chou joined Kleiner Perkins Caufield and Byers in 2013 and focuses on life science investing in medical devices, diagnostics, and digital health. She works

alongside entrepreneurs to develop impactful technologies and therapies for improving patients’ lives. Before joining KPCB, Lynne had over twelve years of healthcare

operating and investing experience. Most recently, Lynne worked for eight years at Abbott Vascular and Guidant in multiple roles and worked on the launch of over ten

interventional cardiology and cardiac surgery product families both in the US and internationally. Most recently, Lynne lead the global launch of Absorb, the world’s first

bioresorbable vascular scaffold, recognized by Wall Street Journal as Medical Device Technology Innovation of the Year and Popular Mechanics. Lynne was responsible

for building the global commercial strategy and therapy development as well as playing a key role in the clinical, reimbursement, operational strategy for the therapy. Earlier

in her career, Lynne worked at Apax Partners with a focus on software venture capital investing. In addition, Lynne worked at Goldman Sachs in the Mergers and

Acquisitions group and worked on multiple multi-billion dollar acquisitions and sell side transactions in various industries.

Partner – Kleiner Perkins Caufield

27

Maneesh Juenja

Maneesh Juneja is CEO and Founder of MJ Analytics. He received a BSc degree in Business & Computing from the University of North London. He has co-authored four

research papers. He attended FutureMed at Singularity University in Feb 2013. His career in ‘Big Data’ has spanned 18 years, including supporting the Whitehall study at

University College London, managing the Tesco database at DunnHumby, and most recently, interrogating the world’s largest US health insurance claims databases at

GlaxoSmithKline R&D. In Feb 2012, he founded the Health 2.0 London Chapter as a volunteer, which has since become the UK’s most dynamic healthcare innovation

ecosystem. In June 2012, he quit his job at GSK to start his own company, MJ Analytics, providing expertise and analytics to the pharmaceutical industry on observational

patient databases. In 2012, determined to expand his mind to new ideas, Maneesh attended pioneering events such as TEDActive, Wisdom 2.0, Open Science Summit

and the Singularity Summit. Outside of work, Maneesh loves exploring new countries. This curiosity has led to trips to 44 countries, including a recent 6 month solo round

the world trip. Maneesh’s vision in life is to generate crowd-sourced evidence on the use of drugs, vaccines, and apps that will impact the health of everyone on the planet.

CEO – MJ Analytics

28

Professor. Mark Ferguson

Professor Mark W.J. Ferguson commenced as Director General of Science Foundation Ireland in January 2012 and as Chief Scientific Adviser to the Government of

Ireland in October 2012.

Previously, Mark Ferguson was appointed Professor in Life Sciences at the University of Manchester in 1984, aged 28, when he was the youngest Professor in Britain. He

has held a number of administrative posts including Head of Department and Dean. He played a key role in the internationally acclaimed restructuring of Life Sciences at

The University of Manchester. Mark has wide ranging research interests which focus on cellular and molecular mechanisms in scarring and wound healing, developmental

mechanisms in normal and cleft palate formation, alligator and crocodile biology. He is the discoverer of scar free embryonic wound healing and temperature dependent

sex determination in alligators and crocodiles. He is the recipient of numerous international awards, prizes, medals and honours for his research work, including the 2002

European Science Prize (jointly), The International Association for Dental Research, Washington USA Craniofacial Biology (2000) and Distinguished Scientist / Young

Investigator (1988) Awards and the Swedish JJ Pindborg International Prize for Research in Oral Biology (1996) and is the author of 327 research papers and book

chapters, 60 patent families and author / editor of 8 books. Mark has supervised over 70 PhD students and been awarded more than £70M in International peer reviewed

research grants from major Research Councils and Charities. He has delivered hundreds of plenary lectures at International Scientific Conferences and contributed to

numerous TV and Radio programmes on Scientific Research and its utilisation.

Director General, Science Foundation Ireland

29

Mark Pollock

Everything I do is about helping people achieve more than they think is possible with a focus on business, science and sport. I am a former Polar adventurer having raced

to the South Pole blind after losing my sight in 1998. Now, after a paralysing fall in 2010, I am exploring the frontiers of spinal injury recovery as the world's leading test pilot

of Ekso robotic legs combined with aggressive physical therapy and innovative electrical stimulation. Check out my story at www.markpollocktrust.org/video Selected by the

World Economic Forum as a Young Global Leader and appointed to the Board of the Christopher and Dana Reeve Foundation (USA), I run a professional speaking

business (www.markpollock.com), am a co-founder of the global running series called Run in the Dark (www.runinthedark.org) and am an ambassador for Wings for Life

Spinal Research Foundation (UK). I hold an honorary doctorate from Queens University Belfast, a diploma in Global Leadership and Public Policy for the 21st Century from

Harvard University and degrees from Trinity College Dublin and The Smurfit Business School.

Motivational Speaker and Author

30

Martin Coulter

Martin Coulter is CEO of Patients Like Me. Coulter was previously Executive Vice President and General Manager of The Advisory Board Company, a publicly traded

healthcare technology and services firm (NASDAQ: ABCO). In that position, he served a range of hospital and healthcare system clients, focusing on establishing best

practice performance through data driven technology and consulting programs. Before that, Coulter served as CEO of Citizens Energy Corporation, a nonprofit healthcare

and energy organization. Earlier in his career, he was a principal at the Parthenon Group and a consultant at Bain & Company. Martin holds a Master’s degree in Business

Administration from Harvard University. Originally an Irish national, he also holds a Master of Science degree in banking from University College, Dublin and a Bachelor of

Arts degree in Economics from Trinity College, Dublin.

CEO - PatientsLikeMe

31

Michael Dilhyon

Michael is a founding member of healthbank, and served as CEO until 2014. In 2013, he was the first Entrepreneur-in-Residence for SystemsX, Switzerland’s largest early

stage life sciences fund, and served as a mentor for the ETH Entrepreneur Lab. Priorly he served as Chairman of Genebio, a bioinformatics software firm, and sat on the

Strategic Advisory Committee for HealthTIES, an EU-backed consortium of four of Europe’s top regions in biosciences. He is also a General Partner with Rollspeed, a

Swiss-based investment fund. Previous to his move to Switzerland, Michael co-founded two US-based firms: Netelligent Corporation and ActiveObjects, where he held the

roles of President, Chairman and CEO respectively.

Presidant, Europe - VitalConnect

32

Missy Krasner

Missy has served as an Executive-in-Residence at Morgenthaler Ventures’ Menlo Park office and is currently a Special Advisor on health IT deals. She has more than

twenty years of product development and marketing, business development, and policy experience in healthcare and health information technology. She currently manages

the healthcare and lifesciences vertical at Box. Missy worked at Google for 5 years in health and consumer marketing and was one of the founding members of Google

Health, an online medical records and wellness platform. In her later years at Google, she managed and led the search launches marketing team. Prior to her role at

Google, Missy worked for the Bush Administration in the Secretary’s Office at the U.S. Department of Health and Human Services (HHS). She was Senior Advisor to Dr.

David Brailer, M.D., Ph.D., the first National Coordinator for Health Information Technology (ONC). Before coming to HHS, she worked as Product Marketing Director for

CareScience, a healthcare information technology company that developed the first Health Information Exchange (HIE). Prior to her role at CareScience, Missy led the

Communications and Research at the Kaiser Family Foundation, a non-partisan, national, healthcare policy think tank. She also worked at Aetna where she spearheaded

provider networking and communications during two corporate mergers to help the company enter the managed care space. She is also a mentor at 500 Startups, a tech

incubator and accelerator in the Silicon Valley and a mentor at Health Box, a new healthcare accelerator out of Chicago, IL. She also advises several health 2.0 startup

companies in the Silicon Valley. She has published a series of articles and blogs and is a member of HIMSS, served on the CCHIT Task Force on PHRs, the Lance

Armstrong International Advisory Council, and the Planned Parenthood International Marketing Advisory Council.

Executive in Residence – Morgenthaler Ventures

33

Dr. Molly Coye

Dr. Molly Joel Coye, M.D., M.P.H., is the Chief Innovation Officer of UCLA Health at the University of California, Los Angeles. She is an internationally recognized leader in

health care delivery policy and an expert in the use of information and clinical technology to advance the health of communities. As Chief Innovation Officer, Dr. Coye

oversees the UCLA Innovates HealthCare Initiative, and is responsible for developing programs and strategies that promote and nurture innovation across the UCLA

Health System. She works with the leadership of the Health System and outside partners to develop innovations that can transform the quality, value and delivery of

healthcare on a local, national and global level. Dr. Coye has extensive experience in government, academia and the private sector. She served as Commissioner of

Health for the State of New Jersey, Director of the California Department of Health Services, and Head of the Division of Public Health Practice at the Johns Hopkins

School of Hygiene and Public Health. She founded and served as chief executive officer of the Health Technology Center (HealthTech), a renowned non-profit education

and research organization that became the premier forecasting institution for emerging technologies in health care. She co-founded and served as chief executive officer

and chair of the Board of Directors of CalRHIO, California’s first statewide health information exchange organization. She was also a founding member of The California

Endowment, the largest private health care philanthropy organization in the state. In her private sector work, she led a large medical group and Independent Physician’s

Association, directed product development at an early internet disease management company and advised venture capital investors in health technology.

Chief Innovation Officer, UCLA Health

34

Dr. Neil Goulbourne

Dr Neil Goulbourne is a GP and Head of Corporate Development and Innovation at Virgin Care concentrating on the development and delivery of the Virgin Care’s strategy

within the healthcare market. Dr Neil Goulbourne has previously held the posts of National Primary Care Lead for Virgin and Clinical Development Lead for Assura.

Head of Corporate Development and Innovation – Virgin Care

35

Noel Toolan

Thirty years of wide ranging international consumer and business marketing and business development experience; at operational, executive, senior management, board,

governmental and consultative level.

CEO - Naloot

36

Oliver Tattan

Oliver is an experienced entrepreneur and investor in the insurance sector. He was the founder and CEO of Vivas Insurance, which from its launch in 2004 was the fastest

growing health insurer in Europe. Vivas was voted ‘Best non-life insurer’ by KPMG in 2006. The company was disposed of to Aviva in 2008. Oliver sits on the board of AGF

International, a Canadian asset manager with CAD$ 7 billion AUM, mainly in equity funds distributed to institutional investors and sovereign wealth funds. He is also a

board member and Chair of the Remuneration Committee of CPL Resources plc, a listed human resources and outsourcing company. Oliver also served as CEO of VHI, a

Government owned € 1 billion revenue insurance company during a time of change and expansion. Earlier he served as CEO of ABT, a Government owned provider of

credit to exporting SMEs. He has also served as a non executive director of a National Industrial Policy Agency. Oliver was co-founder and CEO of Daon, recognised as

the global leader in large scale Government biometric identity management systems and was instrumental in developing border security policies in a number of

jurisdictions. During his career he has held senior positions in Germany, Brazil and South Africa. Oliver was voted Ernst & Young Entrepreneur of the Year 2007. He holds

an MBA from INSEAD in France and a B.E. (Chem.) from University College Dublin. He speaks German and Portuguese.

CEO - Insurance Regulatory Capital

37

Dr. Patricia Silber

Pat is a physician executive and serial entrepreneur who has founded and led both for profit and not for profit organizations. She is currently Founder and CEO of Health

Tech Hatch, a mobile/online platform to promote healthcare startups via video interviews and social media. Hatch is the leading place on the web for healthcare

entrepreneurs to tell their story to the world. She serves on the Advisory Board of a number of healthcare companies listed below. In addition to her entrepreneurial work,

she also consults domestically and internationally on various aspects of health plan and ACO management, including but not limited to, benefit design, population health

management, care coordination, cost reduction, and quality improvement. Specialties: Health Technology, Entrepreneurship, CrowdfundingInnovation, Managed Care,

Medicare Advantage, Large Employer health care purchasing, medical management, disease management, large scale clinical systems implementations, population health

design, implementation, and evaluation

CEO – Health Tech Hatch

38

Raomal Perera

Raomal Perera is a veteran of multiple entrepreneurial ventures and an adjunct professor of entrepreneurship at INSEAD where he currently teaches and studies

entrepreneurship, innovation and the management of rapidly growing companies. Raomal is an educator and loves to work with entrepreneurs. However his primary role is

helping established businesses make innovation work. He uses an interesting mix of his hands-on experience of building successful companies and the more recent

experience of academia and research in helping companies GET, KEEP and GROW their customers, using a number of highly effective tools and processes. Follow his

work on www.LeanDisruptor.com Raomal co-founded two technology companies; ISOCOR was listed on NASDAQ in 1996 and subsequently acquired by Critical Path in

1999. Network365 acquired US company iPin and formed Valista in 2003. Valista was acquired by Aepona in 2009 and Aepona was acqured by Intel in 2013. Raomal also

teaches at a number of other universities on business planning, fund raising, leadership using your emotional capital and customer development using lean methodologies.

Raomal was a recipient of the Irish Software Association’s (ISA) Outstanding Software Achievement Award in 2003. He was also a finalist in the Ernst & Young

‘Entrepreneur of the Year’ awards. Raomal was one of 40 entrepreneurs worldwide chosen to the prestigious World Economic Forum (WEF) as a technology pioneer.

Headed by Raomal, Valista also won a number of industry accolades, ranging from the Wall Street Journal Innovation GOLD award for business, and the Mobile World

Congress Award for the most innovative product. Raomal has an international network of contacts, having built global companies, with a vast geographical footprint. He

setup overseas offices across the globe from East (Japan) to West (USA) and grew companies through acquisitions, partnerships and entering new markets. He has

experience in setting up off-shore engineering facilities.

founder – Thousand Seeds

39

Dr. Robert Kelly

Consultant Cardiologist (special interest in Interventional and Imaging Cardiology). St James Hospital, Beacon Hospital, Vista Cardiology Naas, Whitfield Clinic Waterford,

Ireland.

Entrepreneur and healthcare innovator. I am particularly interested in business model innovation, disruptive innovation in healthcare delivery, connected health, ehealth,

mhealth and telemedicine; use of mobile technology to improve healthcare delivery. As Cardiologist this includes areas such as chronic disease, cardiac risk factors, stroke

and heart attack prevention.

I am interested in disruptive business model innovations that improve healthcare delivery; I have expertise in healthcare as physician and consumer and head of cardiology

division at Beacon. I have recently completed an MBA and I am co-founder & medical director of cloud computing service that provides second opinions to primary care for

reading ECG and cardiac tests (www.connecteddiagnostics.com)

I am principal investigator and co-investigator of several clinical studies looking at stroke prevention in patients at risk for atrial fibrillation. These studies utilse novel sensor

and cardiac monitoring technology.

Health of Cardiology – Beacon Clinic

40

Dr. Ronan Kavenagh

Ronan is a Rheumatologist, speaker, blogger and social media enthusiast. He has a special interest in the management of inflammatory arthritis, osteoporosis and runs a

clinic for musicians with musculoskeletal problems. Ronan is a former president and secretary of the Irish Society for Rheumatology and a founding member of Performing

Arts Medicine Ireland and a member of the British Association of Performing Arts Medicine, Performing Arts Medicine Association (USA) and the American College of

Rheumatology.

Consultant Rheumatologist – Western Rheumotology

41

Shay Garvey

Shay is a founding partner of Frontline Ventures and one of the most active and experienced early stage technology investors in Europe. He was part of the core team of

Delta Partners that raised 4 funds and €235m between 1994-2007. He has invested in 25 early stage tech companies and achieved exits over a number of cycles. He has

deep networks among investors and the entrepreneurial community in Ireland and USA. Earlier in his career Shay worked in industry with Exxon and Corning before joining

McKinsey. Shay then returned to Ireland and spent seven years in the Irish start up scene as a founder/investor in two companies and CEO of a major food exporter before

joining the venture capital industry. Shay has served on the boards of the Irish Venture Capital Association, the Trinity College Science Gallery and the Harvard Business

School European Leadership Council.

Partner – Frontline Ventures

42

Shridhar Iyengar, Phd

Prior to Co-founding Misfit Wearables Dr. Sridhar Iyengar, Founded Agamatrix, Inc. in 2000 and served as Chief Technology Officer, and Director. With 10 years of

research and engineering experience in DSP and mathematical modeling of chemical systems, Dr. Iyengar drove the implementation of AgaMatrix's technology vision. He

is the leading expert in the core DSP/electrochemistry interdisciplinary approach used by AgaMatrix. Combining his background in electrical engineering and biological

sciences, Dr. Iyengar conceived and pioneered the concept of using a DSP approach to enhance biosensor performance. He served as Director of Agamatrix, Inc. His work

in the years following his breakthrough Ph.D. research is the cornerstone for AgaMatrix's intellectual property with two key patents filed under his name and another three

defensive patents to be filed during the summer of 2002. He obtained his Ph.D. from the University of Cambridge as a Marshall Scholar.

Director – Misfit Wearables

43

Steve Suentjens

Stephen Seuntjens holds a Masters in International Management and a Bachelor of Science in Business Administration, Accounting and has over 20 years of global

experience in building and developing new businesses, both organically as well as through M&A (buy & sell). He has worked and lived in Minneapolis, Tel Aviv, London

and Amsterdam. This experience includes both executive positions in multinationals as well as entrepreneurial endeavors. Companies he has supported include Mind CTI,

and Israeli-based, Nasdaq-listed software billing provider; Shapeways, as US based portal company allowing creatives to realize their objects through 3D printing and

Directlife, a Dutch company part of Royal Philips Electronics, motivating individuals to become more physically active through monitoring and coaching. Prior to PHS

Capital, Stephen Seuntjens was CEO of Philips Lifestyle Incubator. Lifestyle Incubator invests in both service and product concepts within the wellbeing / consumer health

domain.

Personal Health Solutions

44

Terry McGuire

As a co-founder and general partner of Polaris Partners, Terry McGuire brings more than 25 years of successful early stage investing experience in healthcare and

technology companies. Prior to starting Polaris in 1996, Terry spent 7 years at Burr, Egan, Deleage & Co. investing in early stage medical and information technology

companies. Terry began his career in venture capital at Golder, Thoma and Cressey in Chicago. As a venture capitalist, Terry has invested in 48 companies. He also co-

founded three companies: Inspire Pharmaceuticals (public), AIR (sold to Alkermes) and MicroCHIPS (private). In 2009, Terry was the recipient of the Massachusetts

Society for Medical Research Award. In 2005, he received the prestigious Albert Einstein Award for Outstanding Achievement in Life Sciences. Terry is emeritus chairman

of the National Venture Capital Association, which represents ninety percent of the venture capitalists in the United States. He is also the chairman of Global Venture

Capital Congress. Terry chairs the board of the Thayer School of Engineering, Dartmouth College. He also sits on the boards of MIT’s The David H. Koch Institute for

Integrative Cancer Research and The Arthur Rock Center for Entrepreneurship at HBS.

Co-founder and General Partner - Polaris Partners

45

Tony Zappala

Tony joined as a Partner of Highland Capital Partners Europe in 2013. He focuses on growth-stage investments primarily in consumer internet and enterprise software

sectors. Tony currently represents Highland Europe on the boards of AMCS Group, Intersec, Talentsoft, and WeTransfer, and is involved with the investment in

Malwarebytes and Social Point. Prior to joining Highland, Tony worked with Index Ventures for over 7 years, where he was part of the team which raised and invested the

firm’s first dedicated Growth fund in 2007 and second fund in 2011. While at Index Tony gained extensive board experience with companies such as Privalia, Moleskine

(Milan: MSK), Nasty Gal, Milestone Systems, Ozon, RPX (Nasdaq: RPXC), Telegent (Spreadtrum) and VirtualLogix (Redbend). Tony previously worked with

STMicroelectronics in Corporate Development and M&A and with LEK Consulting in London and Boston. Tony is a British and Italian national, and holds an M.Eng in

Electrical and Information Sciences from Cambridge and an MBA from INSEAD. In his spare time he enjoys spending time with his wife and two daughters as well as

training for and competing in triathlons.

Partner - Highland Capital Partners

46

Dr. Vishal Gulati

Vishal has been a specialist healthcare investor in diagnostics, devices, healthcare and biotechnology and has served on the boards of companies across Europe, the USA

and in India for over ten years. He gained investment management experience at Atlas Venture (US$ 2.5bn under management), The Wellcome Trust (one of the world's

largest medical foundations with an endowment of £ 13bn) and at a series of investment ventures including Ivy Lane Capital (UK and Mauritius). Having been a practicing

physician, Vishal is able to combine the insights from a technical as well as a financial perspective. Vishal qualified in medicine in India and received his postgraduate

training in Oxford as a Rhodes Scholar (1995-1998).

Partner - DFJ Esprit

47

Dr. Vitor Asseituno

Physician with MBA on Finance. Founder of ES Media, a leading healthcare media group in Latin America. Chairman of Health 2.0 Latin America. Vitor also worked in

venture capital, angel investment, startups and the incubator Rock Health, besides being a doctor at the Air Force, Full Member of the Brazilian Society fo Health

Informatics and Member of the HL7 International. Vitor also organized the HealthXL Award for Latin America.

CEO – Live Healthcare Media

48

David Feygin, Phd

As Vice President of Corporate Strategic Innovation for Becton Dickinson (BD), David is responsible for integrating company-wide activities focused on the identification of

new market opportunities outside of existing core areas, the development of high-impact growth concepts that fall outside of, or cut across, existing business units and

incubation of non-core offerings. David is currently leading BD’s information-enablement efforts to ensure successful entry into Health IT. David is Chair of the Executive

Council for The Center for Patient Safety Research and Practice, a thought leader in healthcare safety with a primary focus on medication error and patient safety research.

As World-Wide Director of Strategic Innovation for the BD - Medical Surgical Systems (MSS) business unit, David developed and led the MSS Strategic Innovation Group

which is responsible for identifying, developing and validating opportunities and overall growth strategies. David has driven global strategy development efforts and

business development activities that enabled growth through innovation. The Strategic Innovation Group is responsible for strategic marketing, market analytics,

opportunity sensing, sourcing and evaluation, health economics analysis, fundamental business analytics, advanced customer research and driving innovation initiatives

from market, clinical, technical and policy perspectives. David received a Ph.D. in Mechanical Engineering from U.C. Berkeley for his work in virtual environments and

medical simulation. He spent four years at medical simulator startups leading the development, commercialization and launch of state-of-the-art simulators including the

Virtual I.V.TM product line. Prior to joining BD, David received an M.B.A. from the Harvard Business School.

VP, Corporate Strategic Innovation – Becton Dickinson

49

Noel Harvey, Phd

Noel Harvey is Vice President, Research and Development at BD Technologies in Research 5344 HarveyTriangle Park, NC. As a component of BD’s Office of Science,

Medicine, and Technology, BD Technologies is tasked with identifying and developing innovative new technology that can be applied to new products that meet significant

unmet medical needs across the globe. Dr. Harvey has initiated and led collaborative research and development programs funded by Pfizer, Eli Lilly, Amgen, the National

Institutes of Health, the Bill and Melinda Gates Foundation, and the US Department of Defense. All of these collaborations were centered on use of device technology to

improve healthcare practices in the developed and developing worlds. Noel has also represented BD in Washington DC on matters regarding biodefense, pandemic

preparedness, and vaccine policy and is a frequent review panelist for the National Institutes of Health and the National Science Foundation. Dr. Harvey holds a PhD in

Physical Chemistry from Duke University. A winner of the Howe Award for Technological Innovation, the Haas Award for Scientific Excellence, and the Hauser Award for

Physical Chemistry, he holds over 35 patents and has authored more than 50 peer reviewed scientific publications. He has worked at BD for 20 years.

VP, Research and Development – Becton Dickenson

50

Theresa Heggie

Theresa Heggie was appointed Chief Strategy and Marketing Officer in June 2013. Before joining Bupa, Theresa held a number of key positions in Shire Human Genetic

Therapies. Most recently, she was Senior Vice President of Global Commercial Operations based in Geneva, where she was accountable for the company’s global sales

and marketing functions. Originally from New York State, Theresa has more than 25 years’ experience in the pharmaceutical industry, having worked at Janssen

Pharmaceuticals (part of Johnson & Johnson), Ohmeda Pharmaceutical Products Division (part of BOC), and Baxter, in marketing, sales and clinical research roles. She

has a BSc from Cornell University.

Chief Strategy and Marketing Officer – Bupa

51

Dr. Paul Bates

Paul is a passionate healthcare advocate who is strongly focused on improving outcomes for consumers in line with Bupa’s reputation as a healthcare leader. Paul

graduated from medicine with honours in 1985 and has practiced across a wide variety of fields, including paediatrics, obstetrics, accident and emergency, occupational

medicine, surgery and sports medicine. Paul has a Master of Business Administration from INSEAD (France), and has held senior health leadership roles in Europe, Asia

and the United States. Prior to joining Bupa, Paul was the National Medical Director for Innovations at OptumHealth, one of the USA's largest health and wellness

companies. Throughout his career, Paul has developed a strong reputation for leading programs which improve healthcare quality and efficiency, help consumers make

more informed healthcare decisions, and improve their engagement and knowledge of their condition.

Chief Medical Officer – Bupa Australia and New Zealand

52

Dr. Robert Grenfell

Initially trained as a rural General Practitioner. Developed skills in Public Health with extensive experience in Government, Not-For-Profit and Private sectors.

National Medical Director – Bupa Australia and New Zealand

53

Gary Fingerhut

Gary M. Fingerhut is the Executive Director at Cleveland Clinic Innovations. Established in May 2000, Innovations operates as the commercialization arm of Cleveland

Clinic and was recognized by Global Corporate Venturing as number 4 in the world for healthcare corporate venturing. Gary leads a talented team of professionals guided

by some of the nation’s top venture capitalists. The Cleveland Clinic Innovations team has successfully executed over 500 licenses, and created 67 spin-off companies that

have raised more than $910 million in equity investment and commercialization grants. These efforts have resulted in the creation of over 1,100 jobs. Prior to joining

Cleveland Clinic in 2011 Gary held a number of senior level positions at Axentis, of which he is a co-founder.

Executive Director – Cleveland Clinic Innovations

54

Charles Steiner

Charles has been developing and commercializing medical technology for 25 years in the areas of surgical navigation, minimally invasive surgery, surgical simulation,

neuromodulation and healthcare information technology. He currently manages the technology development program for Cleveland Clinic Innovations which invests in

commercially viable projects to validate their technology, de-risk future investments and generate increased value for the intellectual property holder. Charles is the holder

of 6 US Patents, many of which are current components of clinical devices or processes. Charles has advised several early stage medical technology companies through

pre-seed, seed and later rounds of funding. Two companies Charles has advised have been acquired with others approaching monetization. Charles manages the Clinical

Innovation Award for Enterprise Ireland and coordinates the commercialization Steering Committee for Cleveland Clinic Innovations.

Director of Product Development – Cleveland Clinic Innovations

55

Christopher Coburn

Chris Coburn is Vice President, Innovation at Partners HealthCare with responsibility for the commercial application of the unique assets and capabilities of the $10 billion,

Boston based system. Representing Brigham and Women's Hospital, Massachusetts General Hospital, and McLean Hospital, Partners HealthCare is the largest academic

research enterprise in the US with nearly $1.5 billion in sponsored research. Mr. Coburn leads a team of more than 70 staff professionals. Prior to joining Partners in 2013,

Coburn was the founding Executive Director of Cleveland Clinic Innovations. During his thirteen year leadership, Cleveland Clinic spun off 57 companies -- before Coburn’s

arrival Cleveland Clinic had none. He also led the establishment of the Clinic’s national Innovation Alliance which provides onsite innovation management for healthcare

systems throughout the U.S. Mr. Coburn has served on numerous corporate and community boards including Autonomic Technologies, Explorys, and the U.S. Enrichment

Corporation (NYSE:USU). He is a member of the National Academy of Sciences Committee on Assessing the Value of Research in Meeting National Goals and IBM’s

Watson Health Care Advisory Board. He is a former Vice President and General Manager of Battelle Memorial Institute. He has consulted, testified and spoken on

innovation and commercialization throughout North America and in nearly 30 countries. He and his wife, Nancy, have three grown children.

President, Innovation – Partners HealthCare

56

Dr. Joseph Kvedar

Joseph (Joe) C. Kvedar is Vice President of Connected Health at Partners HealthCare. He was formerly the Director (and Founder) of the Center for Connected Health. He

is a recognized visionary in his field. The Center for Connected Health creates and studies models for healthcare delivery that move care into the daily lives of patients.

Leveraging information and consumer technologies, the Center helps providers and patients manage chronic conditions, maintain health and wellness, and improve

adherence, engagement and clinical outcomes. The Center is a division of Partners HealthCare, founded by Brigham and Women’s and Massachusetts General Hospitals.

Under Dr. Kvedar’s direction, the Center developed a connected health technology platform that supports its clinical programs and inspired the launch of the first connected

health employee benefit, adopted by EMC Corporation. In 2010, he co-founded personal health technology company Healthrageous, where he is Chair of the Scientific

Advisory Board. Dr. Kvedar grew and formalized the Center’s Consulting Services, which provides product evaluations, feasibility trials, reviews and counsel to companies

seeking to enter the market. Through research, innovation, clinical programs and consulting services, the Center has become a catalyst in the shift to connected

healthcare. Dr. Kvedar is a board-certified dermatologist and Associate Professor of Dermatology at Harvard Medical School; past President and board member of the

American Telemedicine Association; Past Chair of the American Academy of Dermatology Task Force on Telemedicine; and a board member of organizations such as

Continua and Care Continuum Alliance. He is an advisor at Physic Ventures and a mentor at Blueprint Health and Rock Health. Dr. Kvedar authors the popular cHealth

Blog and co-edited Home Telehealth: Connecting Care within the Community, the first book to report on technology to deliver quality healthcare at home. He has authored

60+ publications.

Vice President, Centre for Connected Health – Partners HealthCare

57

Dr. Maulik Majmudar

Maulik D. Majmudar, MD is a physician, scientist, educator, and entrepreneur. He is currently a Cardiology Fellow at the Brigham and Women's Hospital. Maulik attended

medical school at Northwestern Univeristy Feinberg School of Medicine and completed his Internal Medicine residency at The Johns Hopkins Hospital. Maulik's research

interests are in the field of cardiovascular molecular imaging and biomakers (including imaging as a biomarker). He is currently doing his post-doctoral research training in

the laboratory of Matthias Nahrendorf and Ralph Weissleder at the Center for System Biology, at the Massachusetts General Hospital.

Clinical Advisor – Alivecor

Chief Clinical Officer – Quanttus

Associate Director, Healthcare Transformation Lab – Massachusetts General Hospital

58

Nancy Lugn

Nancy’s responsibilities include developing strategic collaborations with industry and intellectual property commercialization in the area of health information technology

(HIT) for Partners HealthCare. Before joining Business Development, Nancy was an Associate Director for Research & Licensing-Massachusetts General Hospital for

Radiology, Anesthesia and the Laboratory for Computer Science. Nancy’s experience includes Director of Operations for Perceptive Informatics a subsidiary of the CRO,

PAREXEL, Inc., Corporate Manager for the Center for Connected Health at Partners HealthCare, Inc., Vice President of International Operations for WorldCare, Inc., and

Director of Medical Services for Radiology Associates/Greystone, Inc. Nancy is a cum laude graduate of Suffolk Law School; she received a M.B.A. from Bryant University,

a B.A. degree from Providence College, and earned a C.A.S. in Clinical Research from the Massachusetts General Hospital Institute of Health Professions. Nancy is a

member of the Massachusetts bar.

Director Business Development – Partners HealthCare

59

Trung Do

Trung is Executive Director of Business Development at Partners HealthCare, where he has overall responsibility for developing and managing strategic alliances with

industry, new business development, and facilitating the marketing of intellectual property from Partners hospitals. Trung’s background includes more than twelve years

experience in business development, management and analytical consulting, product development and strategic operational functions. Prior to Partners, he served as the

Director of Operations at PharMetrics, a venture-backed start-up providing healthcare market insights to the pharmaceutical, biotech, medical device, and health plan

sectors of the market. He began his career in healthcare and life sciences as a consultant with Arthur Andersen and Boston Biomedical Consultants. He currently serves as

a member of the Clinical Translational Research and Innovation Centre's (C-TRIC) international advisory board. Trung holds an MBA and MA from Boston University and

BS from University of California at Irvine.

Executive Director, Business Development – Partners HealthCare

60

Dr. Brendan Buckley

Professor Buckley is ICON’s lead medical expert, representing the company’s position on key scientific, ethical and medical governance matters and he will also provide

guidance and oversight to the medical and scientific groups across ICON. An endocrinologist with over 30 years’ experience, Brendan joined ICON through the acquisition

of Firecrest Clinical in 2011, where he was one of the founders of the company and Senior Vice President of Medical Affairs. Brendan has extensive experience in clinical

trials and chairs several independent Data and Safety Monitoring Boards for medium to large cardio-metabolic and rare disease clinical studies. Brendan is Clinical

Professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland, and has also been director of the university’s European Center

for Clinical Trials in Rare Diseases. He has been a board member of the Irish Medicines Board and of theEuropean Medical Agency (EMA)’s Scientific Advisory Group for

Diabetes and Endocrinology since 2005. He was also a member of the EMA Committee for Orphan Medicinal Products from 2000-2003 and a member of the EMA’s panel

of experts. Professor Buckley is also chairman of the Irish Statutory Anti-Doping Agency and is a member of the UK Anti-Doping Scientific Advisory Board.

Chief Medical Officer - ICON

61

Thomas O’Leary

Tom is ICON's Chief Information officer previous to this he held the position of President of ICON Central Laboratories. He joined the company in Feb-2001 as Manager of

Data management in Dublin, he subsequently went on to set-up ICON's process improvement initiative "IMPROVE" and returned to Data Management to become EU VP

of Data Management before becoming Global Head of Data Management in 2006. From 1994-2001 he worked for SmithKline Beecham and later GlaxoSmithKline and

held positions in Data Management, Project Management and resource Management. He is a graduate of Kingston University in Surrey and a Member of the Royal Society

of Chemistry. He holds a Degree in Medicinal Chemistry and a Masters in Data Management.

Chief Informatics Officer - ICON

62

Wilhelm Muehlhausen

Willie has extensive experience in technological and scientific aspects of ePRO. He has successfully managed a team that build the only dedicated ePRO devices in the

current ePRO market. Within ICON Willie leads a unique team of ePRO scientific and technological experts that have many years of experience. Willie is also an active

member of ISPOR and currently serves as the Vice Director of the ePRO consortium under the C-Path umbrella.

Head of Innovation - ICON

63

Stephen Gold

Stephen Gold is Vice President, WW Marketing & Sales Operations, Watson Solutions, IBM Software Group. He has overall responsibility for the brands marketing

strategy, marketing communications, social media, public relations, analyst relations, sales enablement, demand generation, and events. As a member of the senior

leadership team he is working to help commercialize industry solutions based on IBM’s transformative Watson technology.

CMO Watson Group, VP of Partner Program and VC Investments - IBM

64

Sean Hogan

Sean Hogan is Vice President of IBM Healthcare, globally, and in this capacity is responsible for leading IBM’s healthcare business including strategic direction, investment

decisions and operations. Mr. Hogan’s organization leads the development of IBM’s Healthcare Industry Solutions, business partnerships as well as growth and

investments initiatives. Throughout his professional career, Mr. Hogan has focused on business strategy, innovation and growth – particularly growth that is predicated on

business model transformation and advanced technology. Before assuming his current position, Mr. Hogan held several executive responsibilities within the IBM’s

Healthcare & Life Sciences business. Prior to joining IBM’s Health Care and Life Sciences business, Mr. Hogan was Director, IBM Emerging Business Opportunity group in

IBM Corporate Strategy which focused on creation and launch of new growth businesses for IBM. Prior to joining IBM, Mr. Hogan held leadership positions in several

strategy consulting and successful start-up organizations, including Mainspring, Renaissance Worldwide and Booz Allen Hamilton. Mr. Hogan earned his MBA from

Harvard Business School and his Engineering and undergraduate degrees from Dartmouth College/Thayer School of Engineering. Sean and his wife Jana live in

Ridgefield, CT with their three children, Matthew, Jared and Kate.

General Manager, Healthcare - IBM

65

Dr. Kyu Rhee

Kyu Rhee, MD, MPP, serves as the vice president of Integrated Health Services at IBM, where he has direct global responsibilities for health, safety, medical, and health

benefits design and strategy services. Prior to joining IBM, Rhee was chief public health officer at the Health Resources and Services Administration. He also served as the

director of the Office of Innovation and Program Coordination at the National Institutes of Health, where he led numerous initiatives related to health disparities, innovation,

and partnerships. He was also chief medical officer of Baltimore Medical System, Inc., and served five years as a National Health Service Corps scholar and medical

director at Upper Cardozo Health Center, the largest community health center in Washington, D.C. Rhee received his medical degree from the University of Southern

California. He also holds a master’s degree in public policy from the John F. Kennedy School of Government, Harvard University, with a concentration in health care policy.

VP and Chief Health Director - IBM

66

Marco Mohwinckel

Previously Marco was partner at Janssen Healthcare Innovation in Europe, Middle East and Africa (EMEA). Prior to taking on this role, Marco was heading up the

Neuroscience Business Unit and was a member of the UK Management Committee of Janssen Pharmaceutical Companies of Johnson & Johnson in the UK. In this

capacity he was responsible for driving sales and marketing of the leading Janssen brands in the UK and has launched first-in-kind partnership working models with the

National Health Service. Before joining Janssen as strategic marketing director in the anti-infectives franchise in EMEA in 2007, Marco was principal at the global strategy

consulting firm Monitor Group, where he advised numerous clients in the life science sector across three continents on a wide range of strategic and operational issues.

Marco joined JHI because he believes the group will “contribute to the transformation of Janssen and J&J and play an active role in shaping the future of healthcare,” and

looks forward to meeting the challenges of “rethinking, re-organizing, and optimizing healthcare delivery.” Marco holds a degree in Economics and Business Administration

from Bocconi University in Milan, Italy.

Global Head Integrated Care Solutions, Janssen Healthcare Innovation

67

David Tripi

David is a founding partner at Janssen Healthcare Innovation where he is part of a multi-disciplinary group working toward the goal of propelling the company to become

the leader in the healthcare solution business. Prior to the launch of the JHI team, David was with Johnson & Johnson for over 15 years. In 2007 David moved to San

Diego as the COO of the Pharmaceutical Research & Development site where he was responsible for managing a portfolio of drug development compounds.

Partner, Janssen Healthcare Innovation

68

Ulrich Muehlner, Phd

Ulrich is leading initiatives and programs aimed at increasing the value of the Novartis portfolio globally through identifying, shaping and embedding (“beyond-the-drug”)

technologies and other approaches that enable or enhance the real-world outcomes performance of key Novartis products. Ulrich joined Novartis in August 2009 as

Director Corporate Strategy. In this role, and subsequently as acting Global Head Corporate Strategy, he led the annual Novartis Group strategic planning process as well

as key Group strategic and business initiatives ranging from areas such as corporate portfolio review, value management, business synergies, emerging markets, social

business, digital health/medicine to innovation-driven growth opportunities, corporate business development and venturing.

Global Head Corporate Straegy - Novartis

69

Dr. Arron Nelson

Aaron L. Nelson received his PhD from the University of Pennsylvania, USA, and his MD from Tufts University, Boston, Massachusetts, USA. He completed his

postdoctoral training at the Karolinska University, Sweden. He spent several years working in mechanistic, investigational toxicology at Novartis Institutes for BioMedical

Research in Cambridge, Massachusetts, USA. Aaron is currently developing remote patient monitoring approaches for clinical drug development programs, as part of the

Trials of the Future initiative in Novartis Pharma Development.

Rgeneral Partner – dRx Capital (Jointly owned fund by Novartis and Qualcomm)

70

Konstantin Fiedler, Phd

Konstantin is the Head of Innovation and Development at Linde Healthcare, the largest global provider of product solutions and care services for patients with respiratory

diseases. His and the organization's remit is to change the way healthcare is delivered to this patient population. Konstantin is a seasoned senior life science executive with

global leadership experience in companies like Linde, Danaher, GE Healthcare and SmithKline Beecham. His focus and achievements centre around developing and

delivering growth strategies for innovative products and new business models. He has a broad health industry background covering medical devices, diagnostics,

pharmaceuticals as well as drug discovery and development tools. Konstantin is Austrian, but worked and lived in several countries like USA, UK, Sweden, and Germany.

Chief Innovation Officer, Linde Healthcare

71

Dr. Syed Jafri

Syed Jafri is Global Clinical Director of Linde Healthcare – the healthcare division of the German Industrial gas and engineering company Linde Group – and leads clinical

aspects of global development initiatives ranging from clinical services to medical devices and clinical drug development Initially a theoretical physicist, he moved on to

train as a naval officer (where he served both at sea and in staff positions) and as a physician (in which he specialised in surgery and radiology and undertook on

significant management roles). As a practicing physician he has worked with a number of major device manufacturers’ to develop and commercialise new neurovascular

and cardiovascular products and latterly was also part of an advisory practice that assisted private equity funds in target selection, due diligence and post-acquisition value

maximization.

Global Clinical Director – Linde Healthcare

72

Conor Hanley, Phd

Dr Conor Hanley has recently been appointed as President, Cardiology, Strategic Business Unit, ResMed Inc. In his previous role as ResMed’s Senior Vice-President,

Ventures and Initiatives and Senior Vice-President, Cardiology, Conor had management responsibility for ResMed’s existing cardiology business unit and was also

responsible for ResMed’s growth (both organic and inorganic) in new business areas with a specific focus on the application of existing ResMed products in new medical

applications and also the commercialisation of ResMed Sensor Technologies Ltd. He also serves as a member of the CEO Ops Team. Prior to ResMed Conor was a co-

founder and CEO of BiancaMed a company that spun-out of University College Dublin to commercialise a novel, non-contact method to monitor sleep and breathing in the

home for consumer and medical applications. ResMed Inc acquired BiancaMed in July 2011 which was renamed as ResMed Sensor Technologies Ltd which is now based

at NexusUCD, the Industry Partnership Centre. Prior to BiancaMed, Conor led business development efforts in Europe for hydrogen and fuel cells for Air Products and led

the global technology licensing programme and the North American consumer electronics distribution network at NTera, a printed electronics provider. Conor holds a PhD

in Chemical Engineering from the University of Pennsylvania, BEng from University College Dublin and an MBA from INSEAD.

Senior VP, Chronic Disease - ResMed

73

Klaus Schindhelm, Phd

Dr. Schindhelm is Senior Vice President, Global Applied Research, ResMed Ltd, having joined ResMed in 1998. From January 1995 to June 1998, Dr. Schindhelm was

Professor and Head, Graduate School of Biomedical Engineering, the University of New South Wales. He continues to hold a Chair in Biomedical Engineering at the

University of New South Wales. He has broad experience in medical device technologies in general and in respiratory and sleep technologies in particular. He was the

Founding Chairman of the College of Biomedical Engineers, the Institution of Engineers, Australia and a Founding Fellow of the International Academy for Medical and

Biological Engineering. He currently chairs the Vision Cooperative Research Centre and the Therapeutic Goods Committee for the Therapeutic Goods Administration,

Australia.

Senior VP, Global Applied Research - ResMed

74

Barry O’Brien

Barry O’Brien is a Managing Director within SVB’s Venture Capital and Private Equity Group. His primary focus is Corporate Venture Capital. O’Brien is responsible for

globally developing and fostering long term relationships with the venture units and innovation teams of Fortune 500 Companies in the context of enhancing their access to

the world’s most pioneering start-ups.SVB banks over 50% of the venture backed tech and life science companies in the United States and 80% of the WSJ’s Top VC

Backed Companies. With $23 billion in assets and $42 billion in client funds and more than 1,600 employees, SVB provides commercial, international and private banking

through 34 locations worldwide. Forbes Magazine ranks SVB among America's Best Banks and Fortune considered SVB one of the best places to work.Preceding his

career at SVB, O’Brien was a Diplomatic Officer in the Irish Foreign Service. There, he served as Vice Consul of Ireland to the United States having previously had

postings in Dublin and Belfast. Before joining the Foreign Service, O’Brien worked as a strategy consultant at both BearingPoint in Dublin and PricewaterhouseCoopers in

Sydney.Born in Dublin, Ireland, O’Brien attended University College Dublin and UCD Michael Smurfit Graduate Business School, where he was awarded with a bachelor’s

degree in Economics and a master’s degree in Business Studies.

Managing Director, Venture Capital and Private Equity – Silicon Valley Bank

75

JC Simbana

My role is to deliver SVB’s insights, programs and connections to help life science entrepreneurs succeed.With more than ten years of experience in venture banking and

equity research, I have the experience and network to provide feedback on investment materials and provide targeted introductions to venture capital firms/partners, based

on sector, stage, and geography. I work with life science companies across all sectors, including biotech, medical devices, diagnostics and HCIT, to connect them with

strategic, corporate and venture capital.

VP, Life Sciences and Digital Health – Silicon Valley Bank

76

Glen Giovannetti

Leads a team focused on understanding the evolving needs of companies in the Life Sciences industry, monitoring trends and business drivers, and networking and

informing Ernst & Young professionals serving the life sciences industry globally. The team is also responsible for producing Ernst & Young Thought Leadership

publications on the industry including the annual reports Progressions (Life Sciences), Beyond Borders (Biotechnology, now in its 25th year) and Pulse of the Industry

(Medtech). Glen is a frequent speaker at life sciences industry events around the globe.

Global Life Science Sector Leader - EY

77

Eugene Borukhovich

Results driven & passionate entrepreneur and executive with a proven record in envisioning, leading & executing multi-million dollar revenue and growth initiatives

domestically and abroad. Valued member of executive management teams with key contributions beyond the technology expertise. Strong interpersonal and

communication skills, coupled with vision, business insight, and excellent negotiation and decision-making abilities. Poised to deliver powerful strategies, laying foundations

for creative solutions in revenue growth and market product acceptance. Thrive with creativity during uncertainty. Love startups, game changers and the sharing economy.

VP Healthcare, Softserve

Thank you.